生物科技公司杰龙（GERN）今日盘中股价大涨6.82%，引起投资者的广泛关注。
消息面上，杰龙公司公布了截至3月31日的2025财年第一季度财报。报告显示，公司调整后每股亏损3美分，优于分析师平均预期的4美分亏损，也大幅改善了去年同期9美分的亏损。尽管季度营收3960万美元低于分析师预期的4822万美元，但仍实现了同比12927.3%的显著增长。
值得注意的是，尽管杰龙公司本季度仍录得1984万美元亏损，但其财务状况正在逐步改善。分析师对公司前景保持乐观，目前平均评级为"买入"，12个月目标价中位数为4.00美元。然而，投资者也应当注意到，该公司股价今年以来已下跌62.7%，显示出市场对其表现仍存在担忧。此次财报好于预期或将有助于提振投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.